Stivarga 40 mg Alternative – Regora (Regorafenib) 40 mg Tablet | Beacon Pharmaceuticals

Regora 40 mg (Regorafenib) Tablet by Beacon Pharmaceuticals. Reference brand: Stivarga. multikinase inhibitor; used in selected previously treated colorectal cancer, GIST and liver cancer. Prescription medicine. Brand comparison does not establish interchangeability.

Category:
Description

Product Overview

Regora 40 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Regorafenib. Stivarga is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.

Regora vs Stivarga – Reference Brand Comparison

Stivarga is a recognized reference brand associated with Regorafenib. Regora is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.

Composition and Active Ingredient

Brand: Regora. Active ingredient: Regorafenib. Strength: 40 mg. Dosage form: Tablet. Therapeutic class: multikinase inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.

Therapeutic Uses and Indications

Regorafenib is used in selected previously treated colorectal cancer, GIST and liver cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.

Mechanism of Action – How Regorafenib Works

Regorafenib blocks multiple tumor-associated kinases. This mechanism alone does not establish suitability or effectiveness for an individual patient.

Dosage and Administration

The 40 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.

Contraindications

Contraindications depend on Regorafenib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.

Warnings and Precautions

Important safety considerations include serious liver toxicity, hand-foot reactions and bleeding. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.

Possible Side Effects

Potential adverse effects and serious reactions include serious liver toxicity, hand-foot reactions and bleeding. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.

Drug Interactions

Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.

Pregnancy, Fertility and Breastfeeding

Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.

Storage and Handling

Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.

Why Is Regora Listed as an Alternative to Stivarga?

The comparison helps identify another listed brand containing Regorafenib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.

Manufacturer Information

Listed brand: Regora. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Stivarga. Generic: Regorafenib. Strength: 40 mg. Dosage form: Tablet.

Frequently Asked Questions

What is Regora 40 mg? It is a tablet containing Regorafenib 40 mg according to the supplied Beacon price list. What is it used for? Regorafenib is used in selected previously treated colorectal cancer, GIST and liver cancer, subject to specialist assessment. Can it replace Stivarga? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.

Important Medical Disclaimer

This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.

Additional information
Generic NameRegorafenib
Strength40 mg
ManufacturerBeacon Pharmaceuticals Ltd.
Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Stivarga 40 mg Alternative – Regora (Regorafenib) 40 mg Tablet | Beacon Pharmaceuticals”

Your email address will not be published. Required fields are marked *

Shipping & Delivery